Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Oct 22;8(20):5339-5341.
doi: 10.1182/bloodadvances.2024014060.

Tyrosine kinase inhibitor for CML: all the same?

Lukas Veltmaat  1 , Jorge Cortes  1   2
Affiliations
Comment

Tyrosine kinase inhibitor for CML: all the same?

Lukas Veltmaat et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.C. received consulting fees from Novartis, Pfizer, Sun Pharma, Takeda, Terns Pharmaceuticals, and Bio-Path Holdings, and research support to his institution from Novartis, Sun Pharma, and Ascentage. L.V. declares no competing financial interests.

Comment on

References

    1. Matsumura I, Ohtake S, Atsuta Y, et al. Nilotinib vs. dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study. Blood Adv. 2024;8(20):5237–5247. - PMC - PubMed
    1. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340. - PMC - PubMed
    1. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. - PMC - PubMed
    1. Matsumura I, Ohtake S, Atsuta Y, et al. Nilotinib vs. dasatinib in achieving MR4.5 for newly diagnosed chronic myeloid leukemia: results of the prospective randomized phase 3 study, JALSG CML212. Blood. 2020;136(suppl 1):40–41.
    1. Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902–e911. - PubMed

MeSH terms

Substances